Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease.
about
Interventions for lowering plasma homocysteine levels in kidney transplant recipientsInterventions for lowering plasma homocysteine levels in dialysis patientsInterventions for lowering plasma homocysteine levels in kidney transplant recipientsThe effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysisEfficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trialsFolic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular StudyInterventions for lowering plasma homocysteine levels in dialysis patientsPharmacologic management of chronic reno-cardiac syndromeEffect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials.The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis.Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trialsProtocol of randomized control trial for effectiveness of angiotensin receptor blockers on blood pressure control among euvolemic hypertensive hemodialysis patients.Folic acid supplementation and cardiac and stroke mortality among hemodialysis patients.Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis.The association between B vitamins supplementation and adverse cardiovascular events: a meta-analysisAssociation between B vitamins supplementation and risk of cardiovascular outcomes: a cumulative meta-analysis of randomized controlled trials.Association between adherence to folic acid supplements and serum folate, and plasma homocysteine among hemodialysis patients.Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled TrialsFolic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis.Effect of B-vitamin supplementation on stroke: a meta-analysis of randomized controlled trials.Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease.Relationship of homocysteine with cardiovascular disease and blood pressure.Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease.Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic reviewA Patient with Recurrent Arteriovenous Graft Thrombosis.The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction.Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.Homocysteine lowering and cardiovascular disease risk: lost in translationLow protein nitrogen appearance as a surrogate of low dietary protein intake is associated with higher all-cause mortality in maintenance hemodialysis patients.Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.Plasma protein homocysteinylation in uremia.Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.Negative outcome studies in end-stage renal disease.Effects of pre- vs. intra-dialysis folic acid on arterial wave reflections and endothelial function in patients with end-stage renal disease.Nutrient supplements and cardiovascular disease: a heartbreaking story.Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.The treatment of hyperhomocysteinemia.Evidence-based cardiology in hemodialysis patients
P2860
Q24188051-D84DE54F-0E45-4679-9DB4-B621A9C56794Q24240554-BA54B4EA-3F47-4A28-B1CE-A0AAB92F0D3CQ24240632-678509EF-442E-47D4-915B-AD1BDA1FF331Q24604736-EF9EEAB0-DB39-4908-B650-07B7149EC7C4Q24632223-A1171DEB-95DD-42D9-B7EF-51F19F32D0A9Q24647967-733D5A09-4BE5-4E1B-B9FD-2734FE14782DQ26471859-1F20DD64-A03F-4718-A876-F8B44FBF2C5AQ26829812-8220D06D-8AD0-463B-81ED-0B636F4C7829Q30430617-59F87950-94DC-46EE-93B9-53AC122BF151Q33370693-39BAB2CA-B75E-4388-BDCC-37F853018662Q33413288-502BBB06-B076-44AC-8898-21C9BA23E990Q33621194-B90F6408-6D94-446E-A951-8500DA9F3AF9Q33941518-AC156025-335F-40FC-9980-879CF28430E1Q34018699-9A01D43B-4922-4F62-8ECD-30E80705FC24Q34166984-21FE4F87-ED97-426C-8DAC-63D183F0EA9EQ34215572-001D117D-A452-47F6-9ACE-EE36033A16A1Q34234631-166F36F6-1441-4F9C-A50D-1CD358BB07A6Q34537420-0D3DE329-7D74-42EE-A3F8-84CE613D63BFQ34857539-1EE0159C-4FF7-4426-851A-C50993B85154Q35055362-CA7130A3-902E-46E8-A49E-4B256C29A077Q35772112-4FC47C97-D432-4564-9254-C35D4458223CQ35886381-D4A4010A-C05A-4EA7-B951-7CB3D8AA4DA5Q35968147-924E259D-FC8F-47E7-90A0-3432AE4AC789Q36265484-F9CB7BDE-6064-4541-B180-B5C86D851B38Q36349395-4DCF36B7-E190-45D0-AE4F-6FC145065A82Q36609845-10DA2CDC-88A8-40C5-B233-D9A91D658149Q36736622-01854B68-C98B-4341-A052-7B13F02412A1Q36876023-2AC0F01A-0D5A-4444-A524-F6BD78DF0F5CQ36926279-B2D184A8-677E-4804-AA9E-CD627714970BQ36953576-6C768C03-36F9-4FAC-B8D1-548C65276286Q36971844-6EBA98C6-AB44-4E34-BE00-1D9BB0F32585Q36971861-9BADB4BF-1D7B-4247-93D8-550775B66632Q36971878-04B8B6B9-42A5-485D-A44F-6ABFCF3F387EQ37053433-F2B62C4F-7195-46D8-B9FD-00C6316B8CB8Q37142464-913CC7E3-23ED-4CE9-8147-B316756458E4Q37173226-C6837BCF-E210-448C-A4AA-20BF5811DBB0Q37193413-0452B6B1-35AE-492C-8A93-603755E7EC0EQ37251490-A9951604-EAC3-4D8A-A2A5-E73BABE75B83Q37253095-7E165B44-FBE9-4241-8762-0172DFF9D2C9Q37340239-F9D684C4-B50C-4DCA-A175-E482182E2DFD
P2860
Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Randomized trial of folic acid ...... ts in end-stage renal disease.
@en
Randomized trial of folic acid ...... ts in end-stage renal disease.
@nl
type
label
Randomized trial of folic acid ...... ts in end-stage renal disease.
@en
Randomized trial of folic acid ...... ts in end-stage renal disease.
@nl
prefLabel
Randomized trial of folic acid ...... ts in end-stage renal disease.
@en
Randomized trial of folic acid ...... ts in end-stage renal disease.
@nl
P2093
P1476
Randomized trial of folic acid ...... ts in end-stage renal disease.
@en
P2093
Elizabeth M Wrone
James L Zehnder
John M Hornberger
Linda M McCann
Norman S Coplon
Stephen P Fortmann
P304
P356
10.1097/01.ASN.0000110181.64655.6C
P577
2004-02-01T00:00:00Z